

Title (en)
CYTOCHALASIN COMPOSITIONS AND THERAPEUTIC METHODS

Publication
EP 0429585 A4 19920325 (EN)

Application
EP 90907829 A 19900427

Priority
US 34501089 A 19890428

Abstract (en)
[origin: WO9013293A1] The present invention is directed to naturally occurring and synthetic cytochalasin compositions and therapeutic treatments utilizing these compositions. More specifically, the present invention relates to certain synthetic analogues of Cytochalasin B (CB) and sustained release formulations containing a cytochalasin, for example, cytochalasin B and other natural cytochalasins, for example, Cytochalasin D, E, H or J, among others, and one or more of its synthetic analogues. This invention also relates to the surprising discovery that the administration of cytochalasins including CB produces transient immunosuppression which is controllable by dose or route of administration and is reversible spontaneously or with the use of IL-2. Thus, a therapeutic regimen of cytochalasins may be used to treat the undesirable hyperimmunity of transplant patients and patients with autoimmune disease. In addition, anti-tumor therapy utilizing CB and other cytochalasins, and optionally antineoplastic agents other than cytochalasins may be significantly enhanced by combining the administration of these agents with effective amounts of IL-2 or other lymphokines for reversing the immunosuppression produced during administration of cytochalasins with other antineoplastic agents. This invention also relates to sustained release formulations utilizing liposomes or microcapsules which are effective for delivering high concentrations of cytochalasins and optionally, additional antineoplastic agents to the active site of the tumor without producing undesirable immunosuppression.

IPC 1-7
A61K 31/40

IPC 8 full level
C12P 17/18 (2006.01); **A61K 31/40** (2006.01); **A61P 35/00** (2006.01); **C07D 491/044** (2006.01); **C07D 491/10** (2006.01); **C12R 1/645** (2006.01)

CPC (source: EP)
A61K 31/4035 (2013.01); **A61P 35/00** (2017.12); **C07D 491/10** (2013.01)

Citation (search report)
• [X] EP 0291151 A1 19881117 - LEVEEN HARRY H [US], et al
• [XD] EP 0297946 A2 19890104 - UNIV SYRACUSE [US]
• [X] CELLULAR IMMUNOLOGY, vol. 69, 1982, pages 235-247, Academic Press, Inc.; S. STOSIC-GRUJICIC et al.: "Modulation of interleukin 1 production by activated macrophages: in vitro action of hydrocortisone, colchicine and cytochalasin B1"
• [T] CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 32, no. 6, 1991, pages 400-405, Springer Verlag; D. BOGYO et al.: "Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2"
• See references of WO 9013293A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB IT LI LU NL SE

DOCDB simple family (publication)
WO 9013293 A1 19901115; CA 2031520 A1 19901029; EP 0429585 A1 19910605; EP 0429585 A4 19920325; JP H03505744 A 19911212

DOCDB simple family (application)
US 9002342 W 19900427; CA 2031520 A 19900427; EP 90907829 A 19900427; JP 50712690 A 19900427